Enanta Pharmaceuticals Inc
ENTA
Market Cap$160.32M
Close$
$-7.91
200.2% downside
Current Fair Value
200.2% downsideOvervalued by 200.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $160.32 Million |
|---|---|
| Enterprise Value | $163.60 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.48 |
| Beta | 0.77 |
| Outstanding Shares | 21,355,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.66 |
|---|---|
| PEG | 6.08 |
| Price to Sales | 2.63 |
| Price to Book Ratio | 1.97 |
| Enterprise Value to Revenue | 2.54 |
| Enterprise Value to EBIT | -1.74 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.39 |
| Debt to Equity | 0.68 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly